Loop Biz – Lifestyle
Author:
ELI LILLY AND COMPANY
Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
March 16, 2026
←
Previous Page
1
2
3